Grundlæggende statistik
| LEI | 391200VC4LWGA9FR8550 |
| CIK | 1708688 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InflaRx N.V.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 7, 2026 |
InflaRx N.V. 75,000,000 Ordinary Shares Underwriting Agreement May 6, 2026 Exhibit 1.1 InflaRx N.V. 75,000,000 Ordinary Shares Underwriting Agreement May 6, 2026 Guggenheim Securities, LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law, (the “Company”), proposes to is |
|
| May 7, 2026 |
InflaRx N.V. 75,000,000 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273058 PROSPECTUS SUPPLEMENT (To Prospectus dated July 11, 2023) InflaRx N.V. 75,000,000 Ordinary Shares This prospectus supplement relates to the offer and sale of 75,000,000 ordinary shares, nominal value €0.12 per share. Our ordinary shares trade on the Nasdaq Global Market, or Nasdaq, under the trading symbol “IFRX.” O |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of Principal Executive Offices) Indicate by c |
|
| May 6, 2026 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| May 6, 2026 |
SUBJECT TO COMPLETION, DATED MAY 6, 2026 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-38283 InflaRx N.V. (Exact name of Registrant as Specified in Its Charter) Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executiv |
|
| May 6, 2026 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – March 31, 2026 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statem |
|
| May 6, 2026 |
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases Exhibit 99.1 InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases • InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases • Capital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders |
|
| May 6, 2026 |
Exhibit 99.2 CORPORATE PRESENTATION AAV + RENAL STRATEGY May 2026 Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or “we”). This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction in which such offer or solicitation would be unlawful prior to |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| May 4, 2026 |
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes Exhibit 99.1 InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes Jena, Germany, May 4, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new preclinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reacti |
|
| April 28, 2026 |
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Jena, Germany, April 28, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated April 27, 2026, from the Listing Qualifications Department |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 23, 2026 |
DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF INFLARX N.V. Exhibit 99.1 1 This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF INFLARX N.V. On this, the [twenty-third day of April] two thousand and twenty-six, appeared b |
|
| April 9, 2026 |
Exhibit 99.1 InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor Jena, Germany, April 9, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registr |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registr |
|
| April 2, 2026 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the 2026 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on April 23, 2026 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board |
|
| April 2, 2026 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the 2026 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on April |
|
| March 20, 2026 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-273058) on Form F-3 and the registration statements (Nos. 333-221656 and 333-240185) on Form S-8 of our report dated March 20, 2026, with respect to the consolidated financial statements of InflaRx N.V. /s/ KPMG AG Wirtschaftsprüfungsgesellschaft |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 20, 2026 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-273058) of InflaRx N.V. (2) Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant |
|
| March 20, 2026 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Taapken, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 20, 2026 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2025 (the “Report”), I, Thomas Taapken, certify pursuant to |
|
| March 20, 2026 |
Exhibit 16.1 March 20, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 United States Commissioners: We have read Item 16F of the Form 20-F of InflaRx N.V. to be filed on March 20, 2026 and are in agreement with the statements contained in the second and fourth paragraphs therein. We have no basis to agree or disagree with other statements of the Company contained th |
|
| March 20, 2026 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Niels Riedemann, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 20, 2026 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2025 (the “Report”), I, Niels Riedemann, certify pursuant t |
|
| March 19, 2026 |
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones Exhibit 99.1 InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones ● Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR ● Substantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS) ● InflaRx actively reviewing and consid |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| March 16, 2026 |
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Exhibit 99.1 InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Jena, Germany, March 13, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications De |
|
| January 8, 2026 |
Exhibit 99.1 InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation • InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS) • To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| December 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| December 30, 2025 |
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum Exhibit 99.1 InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum • While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indic |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38283 InflaRx N.V. (Exact name of Registrant as Specified in Its Charter) Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executiv |
|
| November 10, 2025 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial st |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| November 10, 2025 |
Exhibit 99.1 InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) • Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern • In HS, over 4 weeks of therapy, InflaRx observed rapid and cl |
|
| November 10, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| November 10, 2025 |
Exhibit 99.2 INF904 Topline Phase 2a Data Hidradenitis suppurativa (HS) & chronic spontaneous urticaria (CSU) NOVEMBER 10, 2025 1 Speakers 2 Niels Riedemann, M.D., Ph.D. Chief Executive Officer, Founder, InflaRx Camilla Chong, M.D. Chief Medical Officer, InflaRx Prof. John Ingram Clinical Professor & Consultant Dermatologist, Cardiff University & Specialty Lead for Dermatology, Health and Care Res |
|
| September 12, 2025 |
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Jena, Germany, September 12, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the Listing Qualifications Dep |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the |
|
| August 7, 2025 |
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update ● INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025 ● Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, |
|
| August 7, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| August 7, 2025 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – JUNE 30, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial stateme |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| July 14, 2025 |
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Exhibit 99.1 InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Jena, Germany, July 11, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Depa |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| June 11, 2025 |
June 11, 2025 Thomas Taapken Chief Financial Officer InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany Re: InflaRx N.V. Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-38283 Dear Thomas Taapken: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review |
|
| June 3, 2025 |
InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany June 3, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracie Mariner and Jenn Do Re: InflaRx N.V. Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-38283 Dear Ms. Mariner and Ms. Do: This letter sets forth the |
|
| May 28, 2025 |
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum EX-99.1 2 ef20049783ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum Jena, Germany, May 28, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) conducting |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| May 22, 2025 |
May 22, 2025 Thomas Taapken Chief Financial Officer InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany Re: InflaRx N.V. Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-38283 Dear Thomas Taapken: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by provid |
|
| May 7, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| May 7, 2025 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – MARCH 31, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statem |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| May 7, 2025 |
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update • Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials • Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable markets • Interim ana |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 24, 2025 |
DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF INFLARX N.V. Exhibit 99.1 This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF INFLARX N.V. On this, the twenty-fourth day of April two thousand and twenty-five, appeared bef |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| April 3, 2025 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the “Principal”). DECLARES AS FOLLOWS 1. The Principal hereby registers for the 2025 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 24, 2025 at 9:00 hours Amsterdam tim |
|
| April 3, 2025 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the 2025 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 24, 2025 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the “AGM”). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board |
|
| March 20, 2025 |
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones Exhibit 99.1 InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones • Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) • Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis f |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 20, 2025 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2024 (the “Report”), I, Thomas Taapken, certify pursuant to 18 U.S.C. Se |
|
| March 20, 2025 |
Exhibit 97.1 31 October 2023 CLAWBACK POLICY INFLARX N.V. PURPOSE InflaRx N.V. (the “Company”), believes that it is in the best interests of the Company and its shareholders and other stakeholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s Board of Directors (the “Board” |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 20, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-273058) of InflaRx N.V. (2) Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant |
|
| March 20, 2025 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Taapken, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 20, 2025 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Niels Riedemann, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 20, 2025 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2024 (the “Report”), I, Niels Riedemann, certify pursuant t |
|
| March 20, 2025 |
Exhibit 11.1 InflaRx N.V. Statement of Policy Concerning Trading in Company Securities V5 revised and adopted December 11, 2024 I. SUMMARY OF POLICY CONCERNING TRADING IN COMPANY SECURITIES This Insider Trading Policy (the “Policy”) provides InflaRx N.V.’s and its subsidiaries’ (collectively, the “Company”) guidelines that it will, without exception, comply with all applicable laws and regulations |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of Principal Executive Offices) Indicate |
|
| February 18, 2025 |
Exhibit 1.1 InflaRx N.V. 8,250,000 Ordinary Shares and Pre-Funded Warrants to Purchase 6,750,000 Ordinary Shares Underwriting Agreement February 13, 2025 Guggenheim Securities, LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: InflaRx N.V., a public limited liability company (naam |
|
| February 18, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273058 PROSPECTUS SUPPLEMENT (To Prospectus dated July 11, 2023) InflaRx N.V. 8,250,000 Ordinary Shares Pre-Funded Warrants to purchase up to 6,750,000 Ordinary Shares This prospectus supplement relates to the offer and sale of 8,250,000 ordinary shares, nominal value €0.12 per share and pre-funded warrants to purchase u |
|
| February 18, 2025 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES INFLARX N.V. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES INFLARX N.V. Number of Ordinary Shares: [] (subject to adjustment) Warrant No. [] Date of Issuance: February [], 2025 (such date, the “Original Issue Date”) InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), hereby certifies that, for good and valuable consideration, the receip |
|
| February 13, 2025 |
SUBJECT TO COMPLETION, DATED FEBRUARY 13, 2025 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| January 15, 2025 |
Exhibit 99.1 InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) Jena, Germany, January 15, 2025– InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted mark |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| December 20, 2024 |
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 Exhibit 99.1 InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 Jena, Germany, December 20, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidrade |
|
| November 15, 2024 |
Exhibit 99.1 InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Jena, Germany, November 15, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regi |
|
| November 8, 2024 |
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update • Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025 • InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVI |
|
| November 8, 2024 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2024 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial st |
|
| November 8, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| August 8, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| August 8, 2024 |
Exhibit 99.1 InflaRx N.V. Unaudited Condensed Consolidated Financial Statements – June 30, 2024 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial stateme |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| August 8, 2024 |
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update ● Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I) ● Initiation of a Phase 2a study with INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected |
|
| June 28, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273058 PROSPECTUS SUPPLEMENT (To Prospectus dated July 11, 2023) Up to $75,000,000 Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink Partners, dated June 28, 2024, relating to the sale of our ordinary shares offered by this prospectus supplement. In accordan |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| June 28, 2024 |
InflaRx N.V. Ordinary Shares (nominal value €0.12 per share) SALES AGREEMENT Exhibit 99.1 InflaRx N.V. Ordinary Shares (nominal value €0.12 per share) SALES AGREEMENT June 28, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), |
|
| June 24, 2024 |
Exhibit 99.1 InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) Jena, Germany, June 24, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| June 5, 2024 |
Exhibit 99.2 InflaRx - virtual R&D event INF904: oral C5aR inhibitor with best-in-class potential in the immuno-dermatology and broader I&I space June 5, 2024 – 12 p.m. EST (US) / 6pm CET (EU) Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or the “Company”). This presentation is made for informational purposes only and does not constitute an offer to |
|
| June 5, 2024 |
InflaRx Hosts R&D Event Highlighting the Promise of INF904 Exhibit 99.1 InflaRx Hosts R&D Event Highlighting the Promise of INF904 • Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & immunology (I&I) more broadly • Addi |
|
| May 21, 2024 |
Exhibit 99.1 InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators Jena, Germany, May 21, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the America |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| May 8, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| May 8, 2024 |
Exhibit 99.1 InflaRx N.V. Unaudited Condensed Consolidated Financial Statements – March 31, 2024 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statem |
|
| May 8, 2024 |
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update ● Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human inflammatory diseases ● INF904 multiple ascending |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 25, 2024 |
DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF inflarx n.V. Exhibit 99.1 This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF inflarx n.V. On this, on the twenty-fifth day of April two thousand and twenty-four, appeared b |
|
| April 4, 2024 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the 2024 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 25, 2024 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the regis |
|
| April 4, 2024 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the “Principal”). DECLARES AS FOLLOWS 1. The Principal hereby registers for the 2024 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 25, 2024 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenst |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 21, 2024 |
Exhibit 99.1 CORPORATE PRESENTATION MARCH 2024 Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or the “Company”). This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. This presentation may not be relied upon in connection with the purchase or sale of any sec |
|
| March 21, 2024 |
Exhibit 97.1 31 October 2023 CLAWBACK POLICY INFLARX N.V. PURPOSE InflaRx N.V. (the “Company”), believes that it is in the best interests of the Company and its shareholders and other stakeholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s Board of Directors (the “Board” |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 21, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-273058) of InflaRx N.V. (2) Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant |
|
| March 21, 2024 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Niels Riedemann, certify pursuant t |
|
| March 21, 2024 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Thomas Taapken, certify pursuant to 18 U.S.C. Se |
|
| March 21, 2024 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Taapken, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 21, 2024 |
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans Exhibit 99.1 InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans ● InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 ● INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidraden |
|
| March 21, 2024 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Niels Riedemann, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 14, 2024 |
IFRX / InflaRx N.V. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ifrx117241sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* InflaRx N.V. (Name of Issuer) Common Shares, nominal value €0.12 per share (Title of Class of Securities) N44821101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appr |
|
| January 25, 2024 |
Exhibit 99.1 InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients • InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. • InflaRx is determined to support broader access to GOHIBIC for eligible patients. Ann Arbor, USA, January 25, 2024 – InflaR |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicat |
|
| January 4, 2024 |
Exhibit 99.2 INF904: TOPLINE RESULTS FROM PHASE I MAD STUDY January 4, 2024 Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or the “Company”). This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. This presentation may not be relied upon in connection with th |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicat |
|
| January 4, 2024 |
Exhibit 99.1 InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 • MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: o Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing pe |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| November 6, 2023 |
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum Exhibit 99.1 InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum • Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. • PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress Jena, Germany, November |
|
| November 1, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| November 1, 2023 |
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.3 InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update • Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoing • Six clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG) • FDA regulatory pathway |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| November 1, 2023 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial st |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| September 11, 2023 |
Exhibit 99.1 InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 • SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: o Safety and tolerability with no signals of concern over entire dose range o Pharmacokinetics (PK): favorable dose-proportional systemic exposure with overall PK profile co |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| August 30, 2023 |
Exhibit 99.1 InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) • MAA for vilobelimab was submitted in July • MAA has been validated by EMA and is now under review • Regulatory submission based on pivotal data from PANAMO Phase III trial • Company announces attendance at upcoming scie |
|
| August 10, 2023 |
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update Exhibit 99.3 InflaRx Reports Second Quarter 2023 Financial Results & Operating Update ● Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States ● Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending dose (MAD) Phase I trial ● Progress in clinical development of vilobelimab in other indi |
|
| August 10, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| August 10, 2023 |
Exhibit 99.1 InflaRx N.V. Unaudited Condensed Consolidated Financial Statements – June 30, 2023 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial stateme |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| July 12, 2023 |
$250,000,000 Ordinary Shares, Debt Securities, Warrants, Purchase Contracts and Units TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-273058 PROSPECTUS $250,000,000 Ordinary Shares, Debt Securities, Warrants, Purchase Contracts and Units InflaRx N.V. (incorporated in the Netherlands) We may offer, from time to time, in one or more offerings, ordinary shares, senior debt securities, subordinated debt securities, warrants, purchase contracts or units, which |
|
| July 7, 2023 |
InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany July 7, 2023 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany July 7, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InflaRx N.V. Registration Statement on Form F-3 Filing Date June 30, 2023 File No. 333-273058 REQUEST FOR ACCELERATION OF EFFECTIVENESS Pursuant to Rule 461 under the Securities Act of 1933, as amended, InflaRx N. |
|
| July 6, 2023 |
United States securities and exchange commission logo July 6, 2023 Niels Riedemann Chief Executive Officer InflaRx N. |
|
| June 30, 2023 |
InflaRx N.V., as the Company as Trustee Senior Indenture Dated as of [●], [●] TABLE OF CONTENTS Exhibit 4.2 InflaRx N.V., as the Company and [●], as Trustee Senior Indenture Dated as of [●], [●] TABLE OF CONTENTS Page ARTICLE 1 Definitions and Incorporation by Reference Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE 2 The Securities Section 2.01 Form and Dating 5 Section |
|
| June 30, 2023 |
As filed with the Securities and Exchange Commission on June 30, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 30, 2023 Registration No. |
|
| June 30, 2023 |
Exhibit 4.3 InflaRx N.V., as the Company and [●], as Trustee Subordinated Indenture Dated as of [●], [●] TABLE OF CONTENTS Page ARTICLE 1 Definitions And Incorporation By Reference Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE 2 The Securities Section 2.01 Form and Dating 6 S |
|
| June 30, 2023 |
Calculation of Filing Fee Tables Form F-3 Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) InflaRx N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) C |
|
| June 28, 2023 |
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer Exhibit 99.1 InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer • Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug development • Dr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR inhibitors Jena, Germany, June 28, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializi |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate b |
|
| June 21, 2023 |
Exhibit 99.1 InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients • Gohibic is now commercially available for hospitals in the U.S. • Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for treatment of certain critically ill COVID-19 patients Jena, Germany, June 21, 2023 – InflaRx N.V. (Nasdaq: |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate b |
|
| May 11, 2023 |
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update Exhibit 99.3 InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update • Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patients • Gohibic planned to be available to patients in the U.S. within the next few weeks • Phase III study with vilobelimab in py |
|
| May 11, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| May 11, 2023 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – MARCH 31, 2023 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statem |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by ch |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 24, 2023 |
IFRX / InflaRx N.V. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2023 |
IFRX / InflaRx N.V. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Shares, nominal value €0.12 per share, of InflaRx N.V. and further agree to the filing of this agreement as an exhibit thereto. In |
|
| April 13, 2023 |
InflaRx N.V. 9,411,765 Ordinary Shares Underwriting Agreement Exhibit 1.1 InflaRx N.V. 9,411,765 Ordinary Shares Underwriting Agreement April 11, 2023 Raymond James & Associates, Inc. As Representative of the several Underwriters listed in Schedule 1 hereto c/o Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, Florida 33716 Ladies and Gentlemen: InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law, (the |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables(1) 424(b)(5) (Form Type) InflaRx N.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| April 13, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-239759 PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2020) 9,411,765 Shares InflaRx N.V. Ordinary Shares This prospectus supplement relates to the offer and sale of 9,411,765 ordinary shares, nominal value €0.12 per share, or ordinary shares. Our ordinary shares trade on the Nasdaq Global Market, or Nasdaq, under the t |
|
| April 11, 2023 |
SUBJECT TO COMPLETION, DATED APRIL 11, 2023 424B5 1 ny20007658x2424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted. Fil |
|
| April 5, 2023 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the “Principal”). DECLARES AS FOLLOWS 1. The Principal hereby registers for the 2023 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 26, 2023 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenst |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-38283 InflaRx N.V. Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641508180 (Address of principal executive offices) Indicate by check mark whether the registr |
|
| April 5, 2023 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the 2023 annual general meeting of shareholders of InflaRx N.V. (the “Company”) to be held on April 26, 2023 at 9:00 hours Amsterdam time (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the “AGM”). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| April 4, 2023 |
Exhibit 99.1 InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients • Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body´s immune response • FDA granted EUA based on Phase III clinical trial results showing a significant relative reducti |
|
| March 22, 2023 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Niels Riedemann, certify pursuant t |
|
| March 22, 2023 |
Exhibit 4.4 [*****] INDICATES OMITTED PURSUANT TO INSTRUCTION 4 AS TO EXHIBITS. THE OMITTED INFORMATION (I) IS NOT MATERIAL, (II) IT WOULD BE COMPETITEVELY HARMFUL IF PUBLICLY DISCLOSED, AND (III) IT IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. Second Addendum to the Co-Development Agreement effective as of November 9, 2021 (hereinafte |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 22, 2023 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Taapken, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 22, 2023 |
Exhibit 2.4 Description of Rights of Each Applicable Class of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 InflaRx N.V.’s (“us, “we,” “our” or the “Company”) ordinary shares are registered under Section 12 of the Securities Exchange Act of 1934, as amended. Our ordinary shares are listed on the Nasdaq Global Select Market under the symbol “IFRX.” We are registered |
|
| March 22, 2023 |
InflaRx Reports Full Year 2022 Financial and Operating Results Exhibit 99.1 InflaRx Reports Full Year 2022 Financial and Operating Results ● Major progress in development of vilobelimab o Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023 o Fast Track and Orphan Drug designations granted for treatment of pyod |
|
| March 22, 2023 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Niels Riedemann, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 22, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-239759) of InflaRx N.V. (2) Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant |
|
| March 22, 2023 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Thomas Taapken, certify pursuant to 18 U.S.C. Se |
|
| March 22, 2023 |
Exhibit 1.1 CONTINUOUS TEXT of the articles of association of InflaRx N.V., with corporate seat in Amsterdam, after amendment to the articles of association, by deed executed before P.C.S. van der Bijl, civil law notary in Amsterdam, on 25 August 2021. Trade Registry number 68904312. This is a translation into English of the original Dutch text. An attempt has been made to be as literal as possibl |
|
| February 13, 2023 |
IFRX / InflaRx N.V. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 5, 2023 |
Exhibit 99.1 InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients • Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) • Trial size to be adapted upon interim analysis with planned total patient number between appr |
|
| January 5, 2023 |
6-K 1 brhc100463066k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of princi |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| December 21, 2022 |
Exhibit 99.1 InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19 • InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China • STS plans to request regulatory |
|
| December 21, 2022 |
Exhibit 10.1 Third Addendum to the Co-Development Agreement (hereinafter referred to as "Addendum") among InflaRx GmbH a corporation established under the law of Germany Winzerlaer Strasse 2, 07745 Jena/Germany (hereinafter referred to as "INFLARX") Staidson (Beijing) BioPharmaceuticals Co., Ltd. ??????????????????? a corporation established under the law of P.R. China 36 Jinghai Er Road. BDA Beij |
|
| December 21, 2022 |
Exhibit 10.2 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of December 21, 2022 between InflaRx N.V., a public limited liability company (naamloze vennootschap) organized under Dutch law (the ?Company?), and Staidson Hong Kong Investment Company Limited, a limited liability company organized under the law of Hong Kong (the ?Purchaser?). The C |
|
| November 9, 2022 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ? SEPTEMBER 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceutical Inc., Ann Arbor, Michigan, United States (together, the ?Group?). The financial sta |
|
| November 9, 2022 |
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 Exhibit 99.1 InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 • Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiated • Study designed as single ascending dose to determine safety, tolerability and pharmacokinetics in healthy volunteers • Future development in complement-mediated chronic diseases Jena |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant’s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| November 9, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated financial statements, including the notes thereto, for |
|
| November 9, 2022 |
Exhibit 99.3 EXPLANATORY NOTE This ?Material Dutch Tax Considerations? section is being provided to update disclosure in InflaRx N.V.?s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission as a result of subsequent changes in Dutch tax law. This section shall be deemed to be incorporated by reference into (i) the registration statem |
|
| November 9, 2022 |
InflaRx Reports Third Quarter 2022 Financial & Operating Results Exhibit 99.4 InflaRx Reports Third Quarter 2022 Financial & Operating Results ? Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA) ? PANAMO Phase III study results in severe COVID-19 published in peer-reviewed journ |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| September 29, 2022 |
Exhibit 99.1 InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients ? Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients ? EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory Medicine ? Request for |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| September 8, 2022 |
Exhibit 99.1 InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine ? The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in invasively mechanically ventilated, critically ill COVID-19 p |
|
| August 5, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EXHIBIT 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated financial statements, including the notes thereto, for |
|
| August 5, 2022 |
EXHIBIT 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceutical Inc., Ann Arbor, Michigan, United States (together, the ?Group?). The financial statemen |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| August 5, 2022 |
InflaRx Reports Second Quarter 2022 Financial & Operating Results EXHIBIT 99.3 InflaRx Reports Second Quarter 2022 Financial & Operating Results ? Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDA ? Plans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announced ? Grant income of ?14.4 million realized during the second quarter ? Cash, cash equivalents and marketable securities o |
|
| July 26, 2022 |
Exhibit 99.1 InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients ? Completed encouraging Type B meeting with US FDA ? Application for EUA planned to be submitted in Q3 2022 Jena, Germany, July 26, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate b |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate b |
|
| July 6, 2022 |
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum Exhibit 99.1 InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum ? US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum ? Fast track follows recently reported orphan drug designation by both US FDA and EMA Jena, Germany, July 6, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutic |
|
| June 29, 2022 |
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19 Exhibit 99.1 InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19 ? Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA ? Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design ? Type B meeting scheduled with FDA; dialogue ongoing with EMA for development in |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate b |
|
| May 12, 2022 |
Exhibit 99.1 INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ? MARCH 31, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceutical Inc., Ann Arbor, Michigan, United States (together, the ?Group?). The financial stateme |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by ch |
|
| May 12, 2022 |
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update Exhibit 99.3 InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update ? Quarter highlighted by progress with vilobelimab in several indications: o Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway o Final data from Phase IIa open-label study in patients with pyoderma gang |
|
| May 12, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes there |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant?s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate by |
|
| April 7, 2022 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the 2022 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on April 28, 2022 at 9:00 hours Amsterdam time (CEST) at Hilton Amsterdam Airport Schiphol, Schiphol |
|
| April 7, 2022 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the 2022 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on April 28, 2022 at 9:00 hours Amsterdam time (CEST) at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, Schiphol, 1118 BN, Schiphol, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 31, 2022 |
Exhibit 99.1 InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients ? Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint ? Pre-specified sensitivity analysis of the primary endpoint |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 24, 2022 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Niels Riedemann, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 24, 2022 |
InflaRx Reports Full Year 2021 Financial and Operating Results Exhibit 99.1 InflaRx Reports Full Year 2021 Financial and Operating Results ? Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa ? Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting ? Topline data in vilobelimab Phase III trial in severe CO |
|
| March 24, 2022 |
Amended and Restated Articles of Association of InflaRx N.V. EXHIBIT 1.1 CONTINUOUS TEXT of the articles of association of InflaRx N.V., with corporate seat in Amsterdam, after amendment to the articles of association, by deed executed before P.C.S. van der Bijl, civil law notary in Amsterdam, on 25 August 2021. Trade Registry number 68904312. This is a translation into English of the original Dutch text. An attempt has been made to be as literal as possibl |
|
| March 24, 2022 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002. EXHIBIT 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Taapken, certify that: 1. I have reviewed this Annual Report on Form 20-F of InflaRx N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 24, 2022 |
EXHIBIT 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2021 (the “Report”), I, Thomas Taapken, certify pursuant to 18 U.S.C. Se |
|
| March 24, 2022 |
Consent of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft. EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statement (Form F-3 No. 333-239759) of InflaRx N.V. 2. Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant To |
|
| March 24, 2022 |
Consent of KPMG AG Wirtschaftsprüfungsgesellschaft. EXHIBIT 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-221656 and No. 333-240185) on Form S-8 and No. 333-239759 on Form F-3 of our report dated April 28, 2020, with respect to the consolidated financial statements of InflaRx N.V. /s/ KPMG AG Wirtschaftspr?fungsgesellschaft Leipzig, Germany March 24 |
|
| March 24, 2022 |
EXHIBIT 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2021 (the “Report”), I, Niels Riedemann, certify pursuant t |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 24, 2022 |
EXHIBIT 2.4 Description of Rights of Each Applicable Class of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 InflaRx N.V.?s (?us, ?we,? ?our? or the ?Company?) common shares are registered under Section 12 of the Securities Exchange Act of 1934, as amended. Our common shares are listed on the Nasdaq Global Select Market under the symbol ?IFRX.? We are registered with |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| March 17, 2022 |
Exhibit 99.1 InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa Jena, Germany, March 17, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received a corrected advice letter from the U. |
|
| March 8, 2022 |
Exhibit 99.1 InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting Jena, Germany, March 8, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that final data from the Company?s Phase IIa open-label study wit |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indicate |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| February 28, 2022 |
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa Exhibit 99.1 InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa Jena, Germany, February 28, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received an advice letter from the U.S. Food and Drug Administration (FDA) re |
|
| February 16, 2022 |
Exhibit 99.1 InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma ? In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concerns ? Steering Committee unanimously voted to continue study as planned and open enrollment for second dosing cohort |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| February 14, 2022 |
IFRX / InflaRx N.V. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
|
| January 10, 2022 |
Exhibit 99.2 Controlling inflammation CORPORATE PRESENTATIONJanuary 2022 Important Notice and DisclaimerThis presentation has been prepared by InflaRx N.V. (?InflaRx?), a US-Nasdaq publicly listed Dutch company having its principal place of business in Germany. This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy se |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 10, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Ind |
|
| January 10, 2022 |
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor Exhibit 99.1 InflaRx Announces New Pipeline Program ? Oral C5aR Inhibitor ? Regulatory discussions on Phase I program have been initiated ? First-in-human study expected to start in the second half of 2022 Jena, Germany, January 10, 2022 ? InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today anno |
|
| January 5, 2022 |
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa Exhibit 99.1 InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa ? Phase III study to include a new primary endpoint, the modified HiSCR ? New primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rd ? Phase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2 |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant's name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indica |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38283 InflaRx N.V. (Translation of registrant?s name into English) Winzerlaer Str. 2 07745 Jena, Germany (Address of principal executive office) Indic |
